Purified transforming growth factor beta

Claim 2

Isolated and substantially homogeneous beta transforming growth factor (TGF-β) having the following characteristics: acid stable; an apparent molecular weight of about 25,000 daltons in the absence of a reducing agent as measured by SDS-PAGE; an apparent molecular weight of about 12,500 daltons under reducing conditions as measured by SDS-PAGE; does not compete with epidermal growth factor for receptor binding; induces dose-dependent formation of large colonies having a size of greater than 3,100 μm 2 of NRK 49F cells in a soft agar assay when activated by epidermal growth factor (EGF) or transforming growth factor-alpha (TGF-α); and being purified to the extent that (1) it does not itself induce NRK cells to form said large colonies in soft agar and (2) a single band with an apparent molecular weight of about 12,500 daltons is shown on SDS-PAGE under reducing conditions and a single band with an apparent molecular weight of about 25,000 is shown under non-reducing conditions.

Claim 3

Isolated and substantially homogeneous beta transforming growth factor (TGF-β) having the following characteristics: acid stable; an apparent molecular weight of about 25,000 daltons in the absence of a reducing agent as measured by SDS-PAGE; an apparent molecular weight of about 12,500 daltons under reducing conditions as measured by SDS-PAGE; does not compete with epidermal growth factor for receptor binding; induces dose-dependent formation of large colonies having a size of greater than 3,000 μm 2 of NRK 49F cells in a soft agar assay in the presence of epidermal growth factor (EGF); and being purified to the extent that (1) it does not itself induce NRK cells to form said large colonies in soft agar and (2) a single band with an apparent molecular weight of about 12,500 daltons is shown on SDS-PAGE under reducing conditions and a single band with an apparent molecular weight of about 25,000 is shown under non-reducing conditions, wherein said TGF-β has the following partial amino acid sequence in a subunit thereof as determined by Edman degradation: Ala-Leu-Asp-Thr-Asn-Tyr-X-Phe-Ser-, where X is undetermined.

Claim 4

Isolated and substantially homogeneous beta transforming growth factor (TGF-β) having the following characteristics: acid stable; an apparent molecular weight of about 25,000 daltons in the absence of a reducing agent as measured by SDS-PAGE; an apparent molecular weight of about 12,500 daltons under reducing conditions as measured by SDS-PAGE; does not compete with epidermal growth factor for receptor binding; induces dose-dependent formation of large colonies having a size of greater than 3,000 μm 2 of NRK 49F cells in a soft agar assay in the presence of epidermal growth factor (EGF); and being purified to the extent that (1) it does not itself induce NRK cells to form said large colonies in soft agar and (2) a single band with an apparent molecular weight of about 12,500 daltons is shown on SDS-PAGE under reducing conditions and a single band with an apparent molecular weight of about 25,000 is shown under non-reducing conditions, wherein said TGF-β has the following partial amino acid sequence in a subunit thereof as determined by Edman degradation: Ala-Leu-Asp-Thr-Asn-Tyr-X-Phe-Ser-, where X is undetermined.

Claim 5

The TGF-β of claim 1, which elicits 50% of its maximal biological response at concentrations less than 5×10 -12 M.

Claim 6

Isolated and substantially homogeneous beta transforming growth factor (TGF-β) having the following characteristics: acid stable; an apparent molecular weight of about 23,000-25,000 daltons in the absence of a reducing agent as measured by SDS-PAGE; an apparent molecular weight of about 13,000 daltons under reducing conditions as measured by SDS-PAGE; does not compete with epidermal growth factor for receptor binding; induces dose-dependent formation of large colonies having a size of greater than 3,000 μm 2 of NRK 49F cells in a soft agar assay when activated by epidermal growth factor (EGF); and being purified to the extent that (1) it does not itself induce NRK cells to form said large colonies in soft agar and (2) a single band with an apparent molecular weight of about 13,000 daltons is shown on SDS-PAGE under reducing conditions and a single band with an apparent molecular weight of about 23,000-25,000 is shown under non-reducing conditions, wherein said TGF-β has the following partial amino acid sequence in a subunit thereof as determined by Edman degradation: ##STR6## where CMC is Half-cystine or cysteine, determined as S-carboxymethylcysteine and X is undetermined and wherein said TGF-β causes half-maximal growth of NRK indicator cells in soft agar at about 64-72 pg/ml in the presence of 2 ng/ml of EGF.

Claim 7

Isolated and substantially homogeneous beta transforming growth factor (TGF-β) having the following characteristics: acid stable; an apparent molecular weight of about 23,000-25,000 daltons in the absence of a reducing agent as measured by SDS-PAGE; an apparent molecular weight of about 13,000 daltons under reducing conditions as measured by SDS-PAGE; does not compete with epidermal growth factor for receptor binding; induces dose-dependent formation of large colonies having a size of greater than 3,000 μm 2 of NRK 49F cells in a soft agar assay when activated by epidermal growth factor (EGF); and being purified to the extent that (1) it does not itself induce NRK cells to form said large colonies in soft agar and (2) a single band with an apparent molecular weight of about 13,000 daltons is shown on SDS-PAGE under reducing conditions and a single band with an apparent molecular weight of about 23,000-25,000 is shown under non-reducing conditions, wherein said TGF-β has the following partial amino acid sequence in a subunit thereof as determined by Edman degradation: ##STR6## where CMC is Half-cystine or cysteine, determined as S-carboxymethylcysteine and X is undetermined and wherein said TGF-β causes half-maximal growth of NRK indicator cells in soft agar at about 64-72 pg/ml in the presence of 2 ng/ml of EGF.